Slide Source: Lipids Online Slide Library www.lipidsonline.org LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Slide Source: Lipids Online Plasma Concentration of TNF- and Risk of Recurrent Coronary Events –2.47 (1 st –50 th.

© 2002, Wellsource Inc. C-Reactive Protein A New Test for Cardiovascular Risk Prepared by Don Hall, DrPH Wellsource Inc.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

Cost-Effectiveness of hsCRP Screening 1. Adjunct to Global Risk Assessment 2. Method to Monitor Statin Efficacy in Secondary Prevention 3. Method to Target.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Introduction Lipoprotein(a) [Lp(a)]

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Diabetes Prevention Program (DPP)

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Tailoring Intervention – Effectively Targeting the High-risk Population Cardiovascular Event Reduction in the Higher-Risk Primary Prevention Population.

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L)

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.

Epidemiology of Inflammatory Markers and CHD: Evidence for High-Sensitivity C-Reactive Protein Paul M. Ridker, MD, MPH.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

2013 ACC/AHA cholesterol treatment guidelines

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Copyright © 2017 American Academy of Pediatrics.

AHA 2017 Residual Inflammatory Risk and Residual Cholesterol Risk:

Copyright © 2012 American Medical Association. All rights reserved.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

by Qi Sun, Monik C. Jiménez, Mary K. Townsend, Eric B. Rimm, JoAnn E

Association of blood lipids with AF

TNT: Baseline and final LDL cholesterol levels

Adjusted mortality risk

A: Epidemiology update

Lipoprotein insulin resistance score and risk of incident diabetes during extended follow- up of 20 years: The Women's Health Study Paulo H.N. Harada,

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Relative risk of hypertension by quintiles of lipids (mg/dL)

Description of studies for pooled analyses

2013 ACC/AHA cholesterol treatment guidelines

Cystatin C levels and risk of death from all causes

Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Baseline Characteristics of the Study Participants

Baseline Characteristics of the Subjects*

Women’s Health Study: Baseline Characteristics Part 1

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Adjusted relative risk Adjusted odds ratio

End point Valsartan Valsartan+HCTZ p

Determinants of moderate Cardiovascular Health Index Score (CHIS) (achieving three or more risk factor targets). Determinants of moderate Cardiovascular.

Presentation transcript:

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565. Copyright, ©2002 Massachusetts Medical Society. Event-Free Survival by Baseline Quintiles of CRP and LDL-C: Women's Health Study C-Reactive Protein, mg/L Probability of Event-free Survival (0.49) (0.50–1.08) (1.09–2.09) (2.10–4.19) (>4.19) (97.6) (97.7–115.4) (115.4–132.2) (132.3–153.9) (>153.9) st 2nd 3rd 4th 5th Quintile 1st 2nd 3rd 4th 5th Quintile

Slide Source: Lipids Online Slide Library Relative Risk for a First CV Event by Baseline CRP Quintile: Women's Health Study RR (95% CI) p Area under ROC CRP quintile12345 mg/L  – – –4.19 >4.19 Crude (1.1–2.7) 2.3 (1.5–3.4) 3.2 (2.2–4.8) 4.5 (3.1–6.6) < Age-adjusted (1.0–2.4) 1.8 (1.2–2.8) 2.5 (1.7–3.7) 3.6 (2.5–5.2) < RF-adjusted* (0.9–2.2) 1.6 (1.1–2.4) 2.0 (1.3–3.0) 2.3 (1.6–3.4) < All models adjusted for treatment assignment. *Risk factors: age, smoking status, diabetes, blood pressure, HRT Ridker PM et al. N Engl J Med 2002;347:1557–1565. Copyright, ©2002 Massachusetts Medical Society.

Slide Source: Lipids Online Slide Library Relative Risk for a First CV Event by Baseline LDL-C Quintile: Women's Health Study All models adjusted for treatment assignment. *Risk factors: age, smoking status, diabetes, blood pressure, HRT RR (95% CI) p Area under ROC LDL-C quintile mg/dL  – – –153.9 >153.9 Crude (0.8–1.4) 1.3 (1.0–1.8) 1.8 (1.4–2.4) 2.2 (1.7–2.9) < Age- adjusted (0.7–1.3) 1.1 (0.9–1.5) 1.5 (1.1–1.9) 1.7 (1.3–2.2) < RF*- adjusted (0.7–1.2) 1.1 (0.8–1.4) 1.3 (1.0–1.7) 1.5 (1.1–2.0) < Ridker PM et al. N Engl J Med 2002;347:1557–1565. Copyright, ©2002 Massachusetts Medical Society.

Slide Source: Lipids Online Slide Library Multivariable-Adjusted Relative Risk CRP < median, LDL < median (1.0–2.1) Ridker PM et al. N Engl J Med 2002;347:1557–1565. Multivariable-Adjusted Relative Risk for First CV Event by CRP and LDL-C above or below the Median: WHS CRP median CRP > median, LDL < median CRP > median, LDL > median 1.5 (1.1–2.1) 2.1 (1.5–2.8) Median CRP 1.52 mg/L; Median LDL-C mg/dL

Slide Source: Lipids Online Slide Library Multivariable Relative Risk Framingham Estimate of 10-yr Risk, % 0–12–45–9 10 Ridker PM et al. N Engl J Med 2002;347:1557–1565. Multivariable-Adjusted Relative Risk for First CV Event by CRP and Framingham Risk Score and by CRP and LDL-C Categories: WHS LDL-C, mg/dL <130130–160>160 < –3.0 >3.0